Practical Considerations for Detection and Characterization of Sub-Micron Particles in Protein Solutions by Nanoparticle Tracking Analysis

References

1. 1.↵
   1. Zolls S.,
   2. Tantipolphan R.,
   3. Wiggenhorn M.,
   4. Winter G.,
   5. Jiskoot W.,
   6. Friess W.,
   7. Hawe A.

   Particles in therapeutic protein formulations, Part 1: overview of analytical methods. J. Pharm. Sci. 2012, 101, 914–935.

   OpenUrlPubMed
2. 2.↵
   1. Philo J. S.,
   2. Arakawa T.

   Mechanisms of protein aggregation. Curr. Pharm. Biotechnol. 2009, 10, 348–351.

   OpenUrlCrossRefPubMed
3. 3.↵
   1. Mahler H. C.,
   2. Friess W.,
   3. Grauschopf U.,
   4. Kiese S.

   Protein aggregation: pathways, induction factors and analysis. J. Pharm. Sci. 2009, 98, 2909–2934.

   OpenUrlCrossRefPubMed
4. 4.↵
   1. Kiese S.,
   2. Papppenberger A.,
   3. Friess W.,
   4. Mahler H. C.

   Shaken, not stirred: mechanical stress testing of an IgG1 antibody. J. Pharm. Sci. 2008, 97, 4347–4366.

   OpenUrlCrossRefPubMedWeb of Science
5. 5.↵
   1. Wang W.,
   2. Singh S. K.,
   3. Li N.,
   4. Toler M. R.,
   5. King K. R.,
   6. Nema S.

   Immunogenicity of protein aggregates—concerns and realities. Int. J. Pharm. 2012, 431, 1–11.

   OpenUrlPubMed
6. 6.↵
   1. Singh S. K.,
   2. Afonina N.,
   3. Awwad M.,
   4. Bechtold-Peters K.,
   5. Blue J. T.,
   6. Chou D.,
   7. Cromwell M.,
   8. Krause H. J.,
   9. Mahler H. C.,
   10. Meyer B. K.,
   11. Narhi L.,
   12. Nesta D. P.,
   13. Spitznagel T.

   An industry perspective on the monitoring of subvisible particles as a quality attribute for protein therapeutics. J. Pharm. Sci. 2010, 99, 3302–3321.

   OpenUrlCrossRefPubMed
7. 7.↵
   1. Rosenberg A. S.,
   2. Verthelyi D.,
   3. Cherney B. W.

   Managing uncertainty: A perspective on risk pertaining to product quality attributes as they bear on immunogenicity of therapeutic proteins. J. Pharm. Sci. 2012, 101, 3560–3567.

   OpenUrlPubMed
8. 8.↵
   1. Philo J. S.

   A critical review of methods for size characterization of non-particulate protein aggregates. Curr. Pharm. Biotechnol. 2009, 10, 359–372.

   OpenUrlCrossRefPubMed
9. 9.↵
   1. Narhi L. O.,
   2. Jiang Y.,
   3. Cao S.,
   4. Benedek K.,
   5. Shnek D.

   A critical review of analytical methods for subvisible and visible particles. Curr. Pharm. Biotechnol. 2009, 10, 373–381.

   OpenUrlCrossRefPubMed
10. 10.↵
    1. Li Y.,
    2. Lubchenko V.,
    3. Vekilov P. G.

    The use of dynamic light scattering and brownian microscopy to characterize protein aggregation. Rev. Sci. Instrum. 2011, 82, 053106.
11. 11.↵
    1. Helmbrecht C.,
    2. Niessner R.,
    3. Haisch C.

    Photophoretic velocimetry—a new way for the in situ determination of particle size distribution and refractive index of hydrocolloids. Analyst 2011, 136, 1987–1994.

    OpenUrlPubMed
12. 12.↵
    1. Saveyn H.,
    2. De Baets B.,
    3. Thas O.,
    4. Hole P.,
    5. Smith J.,
    6. Van der Meeren P.

    Accurate particle size distribution determination by nanoparticle tracking analysis based on 2-D Brownian dynamics simulation. J. Colloid Interface Sci. 2010, 352, 593–600.

    OpenUrlPubMed
13. 13.↵
    1. Filipe V.,
    2. Hawe A.,
    3. Jiskoot W.

    Critical evaluation of Nanoparticle Tracking Analysis (NTA) by NanoSight for the measurement of nanoparticles and protein aggregates. Pharm. Res. 2010, 27, 796–810.

    OpenUrlCrossRefPubMed
14. 14.↵
    1. Huang F.,
    2. Dempsey C.,
    3. Chona D.,
    4. Suh J.

    Quantitative nanoparticle tracking: applications to nanomedicine. Nanomedicine. (Lond) 2011, 6, 693–700.

    OpenUrlPubMed
15. 15.↵
    1. Bell N. C.,
    2. Minelli C.,
    3. Tompkins J.,
    4. Stevens M. M.,
    5. Shard A. G.

    Emerging techniques for sub-micron particle sizing applied to Stober silica. Langmuir 2012, 28 (29), 10860–10872.

    OpenUrlCrossRefPubMedWeb of Science
16. 16.↵
    1. Patois E,
    2. Capelle M.A.H,
    3. Palais C.,
    4. Gurney R.,
    5. Arvinte T.

    Evaluation of nanoparticle tracking analysis (NTA). J.Drug.Del.Sci.Tech., 2012, 22, 427–433.

    OpenUrl
17. 17.↵
    1. Kumru O. S.,
    2. Liu J.,
    3. Ji J. A.,
    4. Cheng W.,
    5. Wang Y. J.,
    6. Wang T.,
    7. Joshi S. B.,
    8. Midduagh C. R.,
    9. Volkin D. B.

    Compatibility, physical stability, and characterization of an IgG4 monoclonal antibody after dilution into different intravenous administration bags. J. Pharm. Sci. 2012, 101, 3636–3650.

    OpenUrlCrossRefPubMed
18. 18.↵
    1. Jachimska B.,
    2. Wasilewska M.,
    3. Adamczyk Z.

    Characterization of globular protein solutions by dynamic light scattering, electrophoretic mobility, and viscosity measurements. Langmuir 2008, 24, 6866–6872.

    OpenUrlCrossRefPubMedWeb of Science
19. 19.↵
    1. He F.,
    2. Becker G. W.,
    3. Litowski J. R.,
    4. Narhi L. O.,
    5. Brems D. N.,
    6. Razinkov V. I.

    High-throughput dynamic light scattering method for measuring viscosity of concentrated protein solutions. Anal. Biochem. 2010, 399, 141–143.

    OpenUrlCrossRefPubMed
20. 20.↵
    1. Wei Z.,
    2. McEvoy M.,
    3. Razinkov V.,
    4. Polozova A.,
    5. Li E.,
    6. Casas-Finet J.,
    7. Tous G. I.,
    8. Balu P.,
    9. Pan A. A.,
    10. Mehta H.,
    11. Schenerman M. A.

    Biophysical characterization of influenza virus subpopulations using field flow fractionation and multiangle light scattering: correlation of particle counts, size distribution and infectivity. J. Virol. Methods 2007, 144, 122–132.

    OpenUrlCrossRefPubMedWeb of Science
21. 21.↵
    1. Qureshi R. N.,
    2. Kok W. T.

    Application of flow field-flow fractionation for the characterization of macromolecules of biological interest: a review. Anal. Bioanal. Chem. 2010, 399-4, 1401–1411.

    OpenUrl
22. 22.↵
    1. Liu J.,
    2. Andya J. D.,
    3. Shire S. J.

    A critical review of analytical ultracentrifugation and field flow fractionation methods for measuring protein aggregation. AAPS. J. 2006, 8, E580–E589.

    OpenUrlPubMed
23. 23.↵
    1. Zhao B. S.,
    2. Koo Y. M.,
    3. Chung D. S.

    Separations based on the mechanical forces of light. Anal. Chim. Acta 2006, 556, 97–103.

    OpenUrlPubMed
24. 24.↵
    1. Watarai H.,
    2. Monjushiro H.,
    3. Tsukahara S.,
    4. Suwa M.,
    5. Iiguni Y.

    Migration analysis of micro-particles in liquids using microscopically designed external fields. Anal. Sci 2004, 20, 423–434.

    OpenUrlPubMed
25. 25.↵
    1. Zolls S.,
    2. Gregoritza M.,
    3. Tantipolphan R.,
    4. Wiggenhorn M.,
    5. Winter G.,
    6. Friess W.,
    7. Hawe A.

    How subvisible particles become invisible-relevance of the refractive index for protein particle analysis. J. Pharm. Sci 2013, 102, 1434–1446.

    OpenUrlPubMed
26. 26.↵
    1. Salinas B. A.,
    2. Sathish H. A.,
    3. Bishop S. M.,
    4. Harn N.,
    5. Carpenter J. F.,
    6. Randolph T. W.

    Understanding and modulating opalescence and viscosity in a monoclonal antibody formulation. J. Pharm. Sci 2010, 99, 82–93.

    OpenUrlPubMed
27. 27.↵
    1. Demeule B.,
    2. Messick S.,
    3. Shire S. J.,
    4. Liu J.

    Characterization of particles in protein solutions: reaching the limits of current technologies. AAPS. J. 2010, 12, 708–715.

    OpenUrlPubMed
28. 28.↵
    1. Williams P. S.,
    2. Giddings J. C.

    Theory of field-programmed field-flow fractionation with corrections for steric effects. Anal. Chem. 1994, 66, 4215–4228.

    OpenUrlPubMed
29. 29.↵
    S.Kim Ratanathanawongs and Williams Dean Lee. Field-flow fractionation of proteins, polysaccharides, synthetic polymers, and supramolecular assemblies. J.Sep.Sci., 2006, 29, 1720–1732.

    OpenUrl
30. 30.↵
    1. Bloomfield V. A.,
    2. Lim T. K.

    Quasi-elastic laser light scattering. Methods Enzymol. 1978, 48, 415–494.

    OpenUrlPubMed
31. 31.↵
    1. Schersch K.,
    2. Betz O.,
    3. Garidel P.,
    4. Muehlau S.,
    5. Bassarab S.,
    6. Winter G.

    Systematic investigation of the effect of lyophilizate collapse on pharmaceutically relevant proteins I: stability after freeze-drying. J. Pharm. Sci 2010, 99, 2256–2278.

    OpenUrlPubMed